Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of ixazumib, the first oral proteosome inhibitor to be approved for the treatment of multiple myeloma (MM). The clinical trial assessed the effects and safety of different doses of ixazumib, which showed to have considerable single-agent activity in the MM setting.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
To see more videos go to http://www.vjhemonc.com/
Facebook: https://www.facebook.com/vjhemonc
Twitter: https://twitter.com/VJHemOnc